Clicky

InflaRx N.V.(IFRX)

Description: Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.


Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Antibodies Autoimmune Disease Monoclonal Antibodies Clinical Development Monoclonal Antibody Inflammatory Diseases Hidradenitis Suppurativa Complement System Vasculitis C5a

Home Page: www.inflarx.de

IFRX Technical Analysis

Winzerlaer Str. 2
Jena, 07745
Germany
Phone: 49 3641 508 180


Officers

Name Title
Dr. Niels C. Riedemann M.D., Ph.D. Co-Founder, CEO & Exec. Director
Prof. Renfeng Guo M.D. Co-Founder, Chief Scientific Officer & Exec. Director
Dr. Thomas Taapken Ph.D. Chief Financial Officer
Ms. Nicole Bertsch Sr. Director & Head of HR
Dr. Maria Habel PH.D. Head of Preclinical R&D
Ms. Evelyn Roth-Geissler Ph.D. VP & Head of Clinical Operations
Dr. Bruce P. Burnett Ph.D. VP & Head of Medical Affairs
Mr. Christian Schmid VP and Head of Legal Affairs & Corp. Counsel
Mr. Kafi Boaten Sr. Director and Head of Supply & Clinical Trial Supplies
Mr. Peter Hurt Ph.D. Sr. Director and Head of Drug Safety & Pharmacovigiliance

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9727
Price-to-Sales TTM: 0
IPO Date: 2017-11-08
Fiscal Year End: December
Full Time Employees: 55
Back to stocks